2019
Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study
Bhattarai S, Klimov S, Mittal K, Krishnamurti U, Li X, Oprea-Ilies G, Wetherilt C, Riaz A, Aleskandarany M, Green A, Ellis I, Cantuaria G, Gupta M, Manne U, Agboola J, Baskovich B, Janssen E, Callagy G, Walsh E, Mehta A, Dogra A, Shet T, Gajaria P, Traina T, Nggada H, Omonisi A, Ahmed S, Rakha E, Rida P, Aneja R. Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study. Cancers 2019, 11: 995. PMID: 31319547, PMCID: PMC6678933, DOI: 10.3390/cancers11070995.Peer-Reviewed Original ResearchTriple-negative breast cancerAR-positive triple-negative breast cancerAndrogen receptorAR statusPrognostic roleOverall survivalBetter prognosisBreast cancerAR-positive nucleiPatients' overall survivalReliable prognostic markersNegative breast cancerPotential therapeutic targetMulti-institutional studyAR positivityTNBC patientsPoor prognosisPrognostic valuePrimary tumorPatient prognosisIndian cohortPrognostic markerUK cohortAR antibodyTNBC samples
2017
HER3-EGFR score to predict clinical outcomes in triple-negative breast cancer.
Ogden A, Bhattarai S, Green A, Aleskandarany M, Rakha E, Ellis I, Li X, Krishnamurti U, Janssen E, Jonsdottir K, Reid M, Rida P, Aneja R. HER3-EGFR score to predict clinical outcomes in triple-negative breast cancer. Journal Of Clinical Oncology 2017, 35: 11612-11612. DOI: 10.1200/jco.2017.35.15_suppl.11612.Peer-Reviewed Original ResearchTNBC patientsDistant metastasisPrognostic valueBreast cancerCox proportional hazards regressionTriple-negative breast cancerProportional hazards regressionHigher immunohistochemical expressionTop upstream regulatorsMulti-institutional studyMann-Whitney U testCanonical pathwaysTop canonical pathwaysErbB family membersHER3 levelsPreclinical evidenceClinical outcomesHazards regressionHepatic fibrosisImmunohistochemical biomarkersImmunohistochemical expressionLuminal cytokeratinsMultivariable modelEGFR levelsFibrotic processMulti-institutional study of nuclear KIFC1 as a biomarker of poor prognosis in African American women with triple-negative breast cancer
Ogden A, Garlapati C, Li X, Turaga R, Oprea-Ilies G, Wright N, Bhattarai S, Mittal K, Wetherilt C, Krishnamurti U, Reid M, Jones M, Gupta M, Osan R, Pattni S, Riaz A, Klimov S, Rao A, Cantuaria G, Rida P, Aneja R. Multi-institutional study of nuclear KIFC1 as a biomarker of poor prognosis in African American women with triple-negative breast cancer. Scientific Reports 2017, 7: 42289. PMID: 28218233, PMCID: PMC5316996, DOI: 10.1038/srep42289.Peer-Reviewed Original ResearchConceptsDistant metastasis-free survivalProgression-free survivalTNBC cellsOverall survivalPoor prognosisBreast cancerTriple-negative breast cancer patientsTriple-negative breast cancerMultivariable Cox modelMetastasis-free survivalWorse overall survivalBreast cancer patientsMulti-institutional studyAA TNBC patientsAfrican AmericansAfrican American womenTNBC patientsIndependent biomarkerPrognostic valueCancer patientsWorse outcomesCox modelTissue microarrayKIFC1 knockdownTNBC
2016
A multi-institutional study of racial differences in androgen receptor status among triple-negative breast cancers.
Bhattarai S, Xia J, Sonmez Wetherilt C, Pattni S, Klimov S, Riaz A, Aleskandarany M, Green A, Rakha E, Ellis I, Cantuaria G, Li X, Krishnamurti U, Osan R, Rida P, Aneja R. A multi-institutional study of racial differences in androgen receptor status among triple-negative breast cancers. Journal Of Clinical Oncology 2016, 34: 1089-1089. DOI: 10.1200/jco.2016.34.15_suppl.1089.Peer-Reviewed Original Research